Pliant Therapeutics, Inc.

Pliant Therapeutics, Inc. (PLRX) priced its initial public offering on Jun 3, 2020 at $16.00 per share, within its $14.00–$16.00 range, raising $144M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $547.2M. Goodwin Procter advised the company and Cooley advised the underwriters.

Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapies for fibrosis by inhibiting integrin-mediated activation of TGF-beta. Its lead candidate, PLN-74809, is an oral dual integrin inhibitor being developed for idiopathic pulmonary fibrosis and primary sclerosing cholangitis, with Phase 2a trials recruiting.

Status

IPO

Ticker

PLRX

Exchange

Nasdaq Global Select

Priced

Jun 3, 2020

IPO price

$16.00

Price range

$14.00–$16.00

Raised

$144M

Market cap at IPO price

$547.2M

First filed

May 11, 2020

Company counsel

Goodwin Procter

Underwriters' counsel

Cooley

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.